CTLA4 and cancer: Extending our analysis to a pan-cancer cohort receiving immune therapy, patients with high LCP1 expression generally showed better survival outcomes with anti-PD1(P<0.001), anti-PD-L1(P<0.001) or anti-CTLA4 (P<0.001) immune therapy (Fig. 6F-H).